Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Pharmakon Pharmaceuticals, Inc.
483
•Pharmakon Pharmaceuticals, Inc.•March 13, 2014

Pharmakon Pharmaceuticals, Inc. – FDA 483, Mar 13, 2014

Record Details

An FDA inspection conducted at Pharmakon Pharmaceuticals, Inc., an outsourcing facility, from March 5-13, 2014, revealed significant deficiencies in its manufacturing and quality control processes. The observations highlighted a critical lack of adherence to Current Good Manufacturing Practices (CGMP), particularly concerning the production of sterile drug products.Key violations included a failure to establish and follow adequate procedures to prevent microbiological contamination during aseptic processing, such as improper handling practices and insufficient validation of sterile operations. The facility also exhibited inadequate environmental controls, including issues with gowning, cleaning, disinfection, and a deficient environmental monitoring program that did not ensure aseptic conditions were consistently maintained.Furthermore, product testing and release procedures were found to be insufficient. The company released sterile injectable products prior to receiving sterility results, lacked essential method suitability and endotoxin testing, and failed to perform 100% visual inspections for contamination. There were also concerns regarding the lack of documentation for pyrogen-free components and the absence of appropriate segregation for manufacturing certain drug products like cephalosporins. Finally, numerous product labels did not comply with Section 503B(a)(10) of the Act, missing critical information such as the "compounded drug" statement, the facility's address, and dosage forms.Pharmakon Pharmaceuticals, Inc. is required to address these serious observations promptly by implementing comprehensive corrective and preventive actions to ensure compliance with regulatory standards and the safety and quality of its drug products.

Company
Pharmakon Pharmaceuticals, Inc.
Inspection date
March 13, 2014
Product type
Drugs
Office
Detroit District Office
People
  • Sarah M. Napier (Investigator )
  • Emily J. Orban
View Company Profile

ID · b9d92fbd-b702-4832-91c6-d55f8deee7bd

Violation Codes2
21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for Pharmakon Pharmaceuticals, Inc.
  • 483 - 2016-03-16March 16, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pharmakon Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.